Tivic Health FY2022 revenue $1.8M (+46% YoY); cash $3.5M, no debt

Valion Bio, Inc.

2023-Q1 EPS reported -$0.11 revenue$376,000

Revenue $1.8M (+46% YoY); direct-to-consumer sales $1.6M (+114%).
Gross profit $299K vs gross loss of $38K in 2021; 9X gross margin improvement.
Operating expenses: R&D $1.7M, S&M $2.8M, G&A $5.9M (total $10.4M).
Cash $3.5M, no debt; used for operations and attempted acquisition of Reliefband.
CEO cites supply chain challenges but expects growth in 2023.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Valion Bio, Inc. reported the year ending December 31, 2022 results: revenue $1.8 million.

Period: the year ending December 31, 2022
Revenue: $1.8 million
Result: reported results

Exact text from the filing

increased $583 thousand (46%) to $1.8 million for the year ended December 31, 2022

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Valion Bio, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-011178

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.